Back to top

vaccines: Archive

Shaun Pruitt

Is it Time to Buy Pfizer, Moderna, or AstraZeneca's Stock?

Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.

AZNPositive Net Change PFEPositive Net Change MRNAPositive Net Change

Zacks Equity Research

FDA Accepts Sanofi's (SNY) sBLA for Dupixent in Pediatric EoE

If this filing is approved, Sanofi (SNY)/Regeneron's (REGN) Dupixent will be the first FDA-approved treatment for eosinophilic esophagitis in children aged 1 to 11. A final decision is expected in January.

REGNNegative Net Change SNYPositive Net Change BMYNegative Net Change PFEPositive Net Change

Zacks Equity Research

Merck (MRK), Eisai Combo Therapy Fail Two Lung Cancer Studies

Data from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung cancer, fail to achieve their primary endpoints.

NVSNegative Net Change MRKNegative Net Change SGENNegative Net Change ANVSPositive Net Change

Zacks Equity Research

Ligand (LGND) to Spin Out Pelican Subsidiary, Updates '23 View

Ligand (LGND) intends to spin out and merge its subsidiary Pelican with Primordial Genetics to form a new standalone company. Post-merger, it will own a 49.9% stake in this new company.

MRKNegative Net Change JAZZNegative Net Change LGNDNegative Net Change

Zacks Equity Research

CHMP Endorses AstraZeneca's (AZN) Enhertu in Lung Cancer

Data from a mid-stage study shows that treatment with AstraZeneca's (AZN) Enhertu achieved strong and durable tumor responses in certain non-small cell lung cancer patients.

AZNPositive Net Change SELBNegative Net Change DTILNegative Net Change ANVSPositive Net Change

Zacks Equity Research

Moderna (MRNA) Receives CHMP Nod for Updated COVID Vaccine

Clinical data from studies on Moderna's (MRNA) updated COVID vaccine shows improved antibody responses against multiple circulating variants, including BA.2.86, EG.5 and FL.1.5.1 variants.

PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change

Kinjel Shah

Pharma Stock Roundup: FDA Nod to Updated PFE, MRNA COVID Jabs, & More

The FDA authorizes Pfizer (PFE) and Moderna's (MRNA) updated mRNA-based COVID-19 vaccines. Novo Nordisk (NVO) conducts a two-for-one split of its shares and ADRs.

AZNPositive Net Change PFEPositive Net Change NVONegative Net Change MRNAPositive Net Change ABBVNegative Net Change

Zacks Equity Research

Moderna (MRNA) Posts '28 Biz View, Up 3% on Upbeat Flu Jab Data

Moderna's (MRNA) reformulated influenza vaccine candidate meets the primary endpoint in a late-stage study. It expects to launch up to 15 new products in the next five years.

SNYPositive Net Change GSKNegative Net Change MRKNegative Net Change MRNAPositive Net Change

Zacks Equity Research

Moderna (MRNA), Immatics Ink Deal to Develop New Cancer Therapies

The deal will combine Moderna (MRNA) and Immatics' (IMTX) proprietary platforms to develop innovative immunotherapies for cancer.

MRKNegative Net Change MRNAPositive Net Change ANVSPositive Net Change IMTXPositive Net Change

Zacks Equity Research

AstraZeneca (AZN) Posts Upbeat Data on Lung Cancer Drug Combo

Data from a late-stage study shows that AstraZeneca's (AZN) Tagrisso combined with chemotherapy cut the risk of disease progression or death by 38% in certain lung cancer patients.

AZNPositive Net Change GSKNegative Net Change JNJNegative Net Change ANVSPositive Net Change

Kinjel Shah

FDA Approves Pfizer & Moderna's New COVID Booster Vaccines

Pfizer (PFE)/ BioNTech (BNTX), and Moderna's (MRNA) updated mRNA vaccines are now approved for individuals 12 years of age and older and are authorized under emergency use for individuals 6 months through 11 years of age.

PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Moderna (MRNA) Updated COVID Jab Effective Against Pirola Variant

Clinical study data shows Moderna's (MRNA) updated COVID-19 vaccine generates a robust immune response against newer circulating variants, including Pirola and Eris.

PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change

Andrew Rocco

Stocks on the Mend: A Mean Reversion Duo

September is starting in classic, historically weak form. However, if the market finds it's footing, two stocks have explosive, reversion to the mean potential.

AMDPositive Net Change JNJNegative Net Change PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change QQQPositive Net Change

Zacks Equity Research

Novavax (NVAX) Stock Increases 9% in a Month: Here's Why

This growth in Novavax (NVAX) is likely due to the rising COVID-19 infection cases in the United States. Management claims its updated vaccine is effective against the newly emerged virus variants.

PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change